Apollo Tyres / Q2-FY25

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Watch2024-11-12Back to APOLLOTYRE

Revenue

₹6,440 Cr

verified against source

Revenue YoY

3%

reported change

EBITDA

₹880 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
EBITDA (₹ Cr)PositiveWatchNegative
5 actual records
Actual quarterly EBITDA (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q2 FY25: 880 · Watch source sentiment · 2024-11-12Q2 FY25Q3 FY25: 950 · Watch source sentiment · 2025-02-07Q3 FY25Q2 FY26: 1,020 · Positive source sentiment · 2025-11-15Q2 FY26Q3 FY26: 1,190 · Positive source sentiment · 2026-02-10Q3 FY26Q4 FY26: 1,070 · Watch source sentiment · 2026-05-15Q4 FY261,190880
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Apollo Tyres reported a challenging Q2 FY25 with consolidated revenue of ₹6,440 crore (+3% YoY) and EBITDA margin of 13.6%, down ~70bps sequentially due to raw material cost inflation. India revenue was ₹4,460 crore with EBITDA margin of 12.1%, while Europe revenue was €171 million with EBITDA margin of 14.8% (+70bps YoY). Domestic replacement volumes grew mid-single digits, but OEM declined double digits. Management expects RM costs to rise ~1% in Q3 and decline from Q4, with price increases of 2-3% already implemented. Europe shows recovery signs with improved mix (UHP now 47% of PCR volumes). Key risk: competitive pressure and sticky other costs (freight, EPR, advertising) may delay margin recovery.

Colored figures show movement against the previous available record.

Guidance to track

  • Raw material costs to rise slightly in Q3 and start coming down from Q4 onwards.
  • Management expects double-digit growth in TBR and PCR replacement segments for FY25.
  • No change in CapEx guidance; ₹300 crore spent in H1.

Risks flagged

  • Other expenses (freight, EPR, advertising) remained elevated; management expects them to persist near current run rate.
  • Analyst noted margin gap with peers narrowing; management acknowledged focus on profitability may limit volume growth.
  • OEM segment declined double digits; management sees no near-term recovery.

Key quotes

  • My mantra has been profitable growth. And therefore, we are only looking at premiumization of our PCR tires and not going down on pricing.
  • We are doing more analysis to see what has gone wrong and where other expenses have gone up. So, there is a direct focus on all of this.
  • The under-recovery from last year is about 6-odd percent.

Research modules

Go one layer deeper.